Moderna Inc. said its experimental RSV vaccine was 83.7 percent effective in a large clinical trial at lowering the risk of a viral respiratory disease in older adults. The company said it will apply for U.S. approval in the coming months, potentially allowing the vaccine to be on the market by early 2024. (Articles here, here, and here)